JP2002516292A5 - - Google Patents

Download PDF

Info

Publication number
JP2002516292A5
JP2002516292A5 JP2000550512A JP2000550512A JP2002516292A5 JP 2002516292 A5 JP2002516292 A5 JP 2002516292A5 JP 2000550512 A JP2000550512 A JP 2000550512A JP 2000550512 A JP2000550512 A JP 2000550512A JP 2002516292 A5 JP2002516292 A5 JP 2002516292A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
serogroup
carrier
composition according
outer membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000550512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002516292A (ja
JP5074644B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/011977 external-priority patent/WO1999061053A1/en
Publication of JP2002516292A publication Critical patent/JP2002516292A/ja
Publication of JP2002516292A5 publication Critical patent/JP2002516292A5/ja
Application granted granted Critical
Publication of JP5074644B2 publication Critical patent/JP5074644B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000550512A 1998-05-29 1999-05-28 組合わせの髄膜炎菌ｂ／ｃワクチン Expired - Fee Related JP5074644B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8735198P 1998-05-29 1998-05-29
US60/087,351 1998-05-29
US10644698P 1998-10-30 1998-10-30
US60/106,446 1998-10-30
PCT/US1999/011977 WO1999061053A1 (en) 1998-05-29 1999-05-28 Combination meningitidis b/c vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009219818A Division JP2009292851A (ja) 1998-05-29 2009-09-24 組合わせの髄膜炎菌ｂ／ｃワクチン

Publications (3)

Publication Number Publication Date
JP2002516292A JP2002516292A (ja) 2002-06-04
JP2002516292A5 true JP2002516292A5 (enExample) 2006-07-13
JP5074644B2 JP5074644B2 (ja) 2012-11-14

Family

ID=26776879

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000550512A Expired - Fee Related JP5074644B2 (ja) 1998-05-29 1999-05-28 組合わせの髄膜炎菌ｂ／ｃワクチン
JP2009219818A Pending JP2009292851A (ja) 1998-05-29 2009-09-24 組合わせの髄膜炎菌ｂ／ｃワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009219818A Pending JP2009292851A (ja) 1998-05-29 2009-09-24 組合わせの髄膜炎菌ｂ／ｃワクチン

Country Status (14)

Country Link
US (1) US8007815B1 (enExample)
EP (2) EP1079857B1 (enExample)
JP (2) JP5074644B2 (enExample)
AT (1) ATE346609T1 (enExample)
AU (2) AU761495B2 (enExample)
BR (1) BR9910749A (enExample)
CA (1) CA2332963C (enExample)
CY (1) CY1107550T1 (enExample)
DE (1) DE69934225T2 (enExample)
DK (1) DK1079857T3 (enExample)
ES (2) ES2278446T3 (enExample)
NZ (1) NZ508771A (enExample)
PT (2) PT1079857E (enExample)
WO (1) WO1999061053A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
EP1179072A2 (en) 1999-05-19 2002-02-13 Chiron S.P.A. Combination neisserial compositions
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ES2588917T3 (es) * 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
ES2615362T3 (es) 2001-07-27 2017-06-06 Glaxosmithkline Biologicals Sa Adhesinas de meningococos
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
HRP20120433T1 (en) * 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
WO2011024072A2 (en) * 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
BR112015005056A2 (pt) * 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
AU640118B2 (en) * 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
DK0624376T3 (da) 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
DK0710118T3 (da) 1994-04-20 1999-08-09 Us Army Vaccine mod infektioner med gram-negative bakterier
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
PT854729E (pt) * 1995-09-18 2004-08-31 Us Army Med Res Mat Com Usamrm Metodos melhorados para a producao de vacinas de subunidade multivalentes de proteossomas complexados nao covalentemente
DE19601754A1 (de) * 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) * 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
DE69708318T3 (de) * 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
EP0994723A1 (en) * 1997-06-24 2000-04-26 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
JP2001510169A (ja) * 1997-07-17 2001-07-31 ノース アメリカン ワクチン， インコーポレイテッド Ｂ型髄膜炎菌性ポーリンおよびＨ．ｉｎｆｌｕｅｎｚａｅ多糖体を含む免疫原性結合体
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos

Similar Documents

Publication Publication Date Title
CA2314186C (en) Adjuvanted vaccine comprising a cpg oligonucleotide and an antigen from streptococcus pneumoniae
JP5074644B2 (ja) 組合わせの髄膜炎菌ｂ／ｃワクチン
EP1880735A3 (en) Vaccine
CA2392880A1 (en) Compositions comprising neisseria meningitidis antigens from serogroups b and c
JP2011500662A5 (enExample)
JP2004501873A5 (enExample)
NO20002741D0 (no) Vaksine-blandinger omfattende kitosan, for mukosal administrasjon
EP2258385A3 (en) Neisseria vaccine composition
RU2005127200A (ru) Менингококковые вакцины для введения через слизистую оболочку
EP1618889A3 (en) Influenza Vaccine
JP2004512269A5 (enExample)
WO2004041157A3 (en) Group b streptococcus vaccine
AU2457100A (en) Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
EP1955709A3 (en) Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines
JP2001523729A5 (enExample)
EP2277540A3 (en) Polyanionic polymer adjuvants for haemophilus influenza B saccharide vaccines
JP2012521404A5 (enExample)
EP2275122A3 (en) Protein-based streptococcus pneumoniae vaccines
WO2023172741A3 (en) A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine comprising b- and t-cell antigens, immunogenic composition, and uses thereof
JP2017509713A5 (enExample)
CA2332455A1 (en) Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
JP2011514167A5 (enExample)
JP2002531135A5 (enExample)
JP2002502828A5 (enExample)
EP1880734A3 (en) Multi-component vaccine to protect against disease caused by haemophilus influenzae and moraxella catarrhalis